Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): A multicentre randomised phase 3 trial

The Lancet Neurology

Volumn 13, Issue 7, 2014, Pages 666-675

  Kirkpatrick, Peter J ^a   Turner, Carole L ^a   Smith, Christopher ^a   Hutchinson, Peter J ^a   Murray, Gordon D ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE MM; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BRAIN INFARCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SURGEON; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERNATIONALITY; MALE; MIDDLE AGED; SIMVASTATIN; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902548612     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70084-5     Document Type: Article

References (34)

1. Feigin VL, Lawes CMM, Bennett DA, Barker-Callo SL, Parag V Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009, 8:355-369.
2. van Gijn J, Kerr RS, Rinkel GJ Subarachnoid haemorrhage. Lancet 2007, 369:306-318.
3. Epidemiology of aneurysmal subarachnoid hemorrhage in Australia and New Zealand. Incidence and case fatality from the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). Stroke 2000, 31:1843-1850. The Across Group.
4. Molyneux AJ, Kerr RSC, Yu L-M, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups and aneurysm occlusion. Lancet 2005, 366:809-817.
5. National study of subarachnoid haemorrhage. Final report of an audit carried out in 34 Neurosurgical units in the UK and Ireland between 13 September 2001 and 13 September 2002 2006, Clinical Effectiveness Unit RCoSoE, Royal College of Surgeons, London.
6. MacDonald RL Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol 2014, 10:44-58.
7. MacDonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011, 10:618-625.
8. van den Bergh W Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomised controlled trial. Stroke 2005, 36:1011-1015.
9. A/B receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 subarachnoid haemorrhage study group. J Neurosurg 2000, 93:992-997.
10. Siasios I, Kapsalaki EZ, Fountas KN Cerebral vasospasm pharmacological treatment; an update. Neurol Res Int 2013, 2013:1-20.
11. Haley EC, Kassel NF, Apperson-Hansen C, Maile MH, Alves WM A randomised double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 1997, 86:467-474.
12. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989, 298:636-642.
13. van Gijn J, Rinkel GJE Subarachnoid haemorrhage: diagnosis, causes and management. Brain 2001, 124:249-278.
14. Dhar R, Diringer M Statins and anti-inflammatory therapies for subarachnoid hemorrhage. Curr Treat Options Neurol 2012, 14:164-174.
15. Tseng M-Y, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ Effects of acute treatment with Pravastatin on cerebral vasospasm, autoregulation and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage. A phase 11 randomised placebo-controlled trial. Stroke 2005, 36:1627-1632.
16. Tseng M-Y, Hutchinson PJA, Turner CL, et al. Biological effects of acute pravastatin treatment in patients after aneurysmal subarachnoid hemorrhage: a double-blind placebo-controlled trial. J Neurosurg 2007, 107:1092-1100.
17. Delanty N, Vaughan CJ Vascular effects of statins in stroke. Stroke 1997, 28:2315-2320.
18. Vaughan CJ, Delanty N Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999, 30:1969-1973.
19. Chen J, Zhang ZG, Wang Y, et al. Statins induce angiogenesis, neurogenesis and synaptogenesis after stroke. Ann Neurol 2003, 53:743-751.
20. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid haemorrhage: results of a pilot randomised clinical trial. Stroke 2005, 36:2024-2026.
21. McGirt MJ, Lynch JR, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002, 33:2950-2956.
22. Parra A, Kreiter KT, Williams S, et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery 2005, 56:476-484.
23. McHugh GS, Butcher I, Steyerberg EW, et al. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomised controlled trials in traumatic brain injury: results from the IMPACT project. Clin Trials 2010, 7:44-57.
24. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1308.
25. Higgins JPT, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analysis. BMJ 2003, 327:557-560.
26. Velat GJ, Kimball MM, Mocco JD, Hoh BL Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomised controlled trials and meta-analyses in the literature. World Neurosurg 2011, 76:446-454.
27. Kramer AH, Fletcher JJ Statins in the management of patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care 2010, 12:285-296.
28. Sillberg VAH, Wells GA, Perry JJ Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage. A meta-analysis. Stroke 2008, 39:2622-2626.
29. Vergouwen MDI, de Haan RJ, Vermeulen M, Roos YBWE Effect of statin treatment on vasospasm, delayed cerebral ischemia and functional outcome in patients with aneurysmal subarachnoid hemorrhage. A systematic review and meta-analysis update. Stroke 2010, 41:E47-E52.
30. Liu Z, Liu L, Zhang Z, Chen Z, Zhao B Cholesterol reducing agents for aneurysmal subarachnoid haemorrrhage (review). Cochrane Database Syst Rev 2013, 4. CD008184.
31. Chou SH, Smith EE, Badjatia N, et al. A randomised, double blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke 2008, 39:2891-2893.
32. Vergouwen MDI, Meijers JCM, Geskus RB, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomised trial. J Cereb Blood Flow Metab 2009, 29:1444-1453.
33. McGirt MJ, Ambrossi GLG, Huang J, Tamargo RJ Simvastatin for the prevention of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a single-institution prospective cohort study. J Neurosurgery 2009, 110:968-974.
34. Bulters DO, Santarius T, Chia HL, et al. Causes of neurological deficits following clipping of 200 consecutive ruptured aneurysms in patients with good grade aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 2011, 153:295-303.